Edison Investment Research - Basilea Pharmaceutica AG (BSLN) Basilea Pharmaceutica - Ceftobiprole hits its TARGET

Report

Edison Investment Research

Susie Jana

Basilea Pharmaceutica - Ceftobiprole hits its TARGET

Basilea has announced positive top-line data from the Phase III TARGET trial which is evaluating Zevtera/Mabelio (ceftobiprole) in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ceftobiprole, a broad spectrum antibiotic, met primary and secondary efficacy endpoints including non-inferiority to standard of care vancomycin plus aztreonam in the intent-to-treat population. While this news is positive, TARGET is one of two cross-supportive Phase III trials required for the US filing; top-line data from the second study in Staphylococcus aureus bacteraemia (SAB) bloodstream infections (ERADICATE) is expected in H221. A US launch date of 2022/23 for ceftobiprole could be feasible, with a focus on SAB and ABSSSI. We value Basilea at CHF1,082m or CHF100/share.

06/08/2019 3 EN

Underlying

Basilea Pharmaceutica AG

Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.

See profile

CH0011432447 Six Swiss Exchange Switzerland

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Susie Jana

Other Reports on these Companies

GlobeNewsWire

Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das bereit für die klinische Phase-3-Entwicklung ist

Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das bereit für die klinische Phase-3-Entwicklung ist Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 14. August 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es mit Venatorx Pharmaceuticals, Inc. eine exklusive Lizenzvereinbarung zum Erwerb der weltweiten Rechte an Ceftibuten-Ledaborbactam Etzadroxil abgeschlos...

18h / 20m 18h / 20m 1 EN

GlobeNewsWire

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL...

18h / 20m 18h / 20m 1 EN

GlobeNewsWire

Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen

Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen Studie zur Evaluierung der Wirksamkeit und Sicherheit von Fosmanogepix bei Erwachsenen mit invasiven SchimmelpilzinfektionenStudienabschluss im 1. Quartal 2028 erwartet Allschwil, 29. Juli 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es die Phase-3-Studie FORWARD-IM init...

July 29, 2025 July 29, 2025 1 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Basilea Pharmaceutica - Ceftobiprole hits its TARGET

Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das bereit für die klinische Phase-3-Entwicklung ist

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe